APHP - Hopital Bichat

Paris, Île-de-France Region 75018

2 studies enrolling now · 2 studies all time

What they study most

Intermediate Risk Non-Muscle Invasive Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Studies at this site

• Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer — Recruiting now
• A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer — Recruiting now